Study On The Treatment Effects Of BGYH On Rat Acute And Chronic Liver Injury

Baogan Yihao (BGYH) is a compound preparation screened from the traditionalprescriptions by the Dai Medicine Research Institute of Xishuang Banna. It consistsof Mohonia fortunei, Arundina graminifolia, Fructus Crataegi, Schisandra chinensis,Salvia miltiorrhiza, Gentiana scabra and Bupleurum falcatum. BGYH possesses thefunctions of incrasing immunnity, anti-inflammation, antioxidant, clearing heat,liver-protection and enhancing choleresis. It is mainly used in the clinical treatment ofchronic hepatitis B, hepatic fibrosis and liver cirrhosis. In the present study,CCl4/DMN-induced rat acute/chronic models were established to investigate theliver-protective effect of BGYH. Meanwhile, the proliferation inhibition effect ofBGYH drug serum on HSC was also tested.In the acute liver injury study, rats were orally administrated with BGYH at low,medium and high-dose once a day for ten consecutive days.50%CCl4was injectedintraperitoneally2h post the last administration of BGYH at the dose of2mL/kg.24h after the injection, blood and liver were collected. The results showed thatmedium-dose BGYH could significantly lower the levels of ALT and AST in serum.Tissue sections also illustrated that medium-dose BGYH could reduce fattydegeneration and necrosis of hepatocytes. Moreover, the three dose of BGYH couldall decrease the content of MDA in liver tissue indicating that antioxidant might beone mechanism for BGYH to protect the liver.In the chronic liver injury study, high-dose BGYH showed much better curativeeffect. It remarkably lowered the levels of ALT, AST, γ-GT and AKP in serum whileuppering that of Alb. Furthermore, BGYH could also reduce the concentrations of HAand LN in serum with simultaneous decreases of Col-I, Col-IV and Hyp in liver.Tissue sections demonstrated that hepatic fibrosis and the formation of pseudolobulewere both restrained after administration of BGYH. In the preliminary study of themechanism of BGYH in anti-hepatic fibrosis, the amounts of α-SMA and TGF-β wereboth found to be reduced in liver tissue by BGYH. Meanwhile, BGYH drug serumdramatically inhibited the proliferation of HSC. These data suggested that BGYHmight exhibit its anti-hepatic fibrosis effect by down-regulating TGF-β and inhibiting the proliferation of HSC.